|
UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer Clinical research trials and UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer. UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer clinical trial. Human subjects often obtain the finest healthcare possible for their UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "U" Clinical Trials Conditions > UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer  UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer
UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer
For Condition: stage 3 renal cell cancer,stage 4 renal cell cancer,recurrent renal cell cancer
Status: Suspended
Sponsor(s): University of California, San Francisco , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of UCN-01 in treating patients who have unresectable stage III or stage IV kidney cancer.
Details: OBJECTIVES: - Determine the efficacy of UCN-01, in terms of time to objective progression, in patients with stage IV or unresectable stage III renal cell carcinoma. - Determine the objective response rate in patients treated with this drug. OUTLINE: Patients receive UCN-01 IV over 3 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 21-61 patients will be accrued for this study within 15 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed stage IV or unresectable stage III renal cell carcinoma - Metastatic disease must be amenable to biopsy or appropriate for nephrectomy before study therapy - At least 1 unidimensionally measurable lesion - At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan - No known prior or concurrent CNS metastases PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 OR - Karnofsky 60-100% Life expectancy: - More than 3 months Hematopoietic: - WBC at least 3,000/mm^3 - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin normal - AST/ALT no greater than 2.5 times upper limit of normal Renal: - Creatinine normal OR - Creatinine clearance at least 60 mL/min Cardiovascular: - No history of clinically significant coronary artery disease - No symptomatic cardiac dysfunction - No symptomatic congestive heart failure - No unstable angina pectoris - No cardiac arrhythmia Pulmonary: - No symptomatic pulmonary dysfunction Other: - No prior allergic reactions to compounds of similar chemical or biological composition to UCN-01 - No other uncontrolled concurrent illness - No active or ongoing infection - No known immune deficiency - No psychiatric illness or social situation that would preclude study compliance - No insulin-dependent diabetes mellitus - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 6 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered Endocrine therapy: - Not specified Radiotherapy: - At least 4 weeks since prior radiotherapy and recovered - No prior mediastinal radiation Surgery: - See Disease Characteristics - At least 4 weeks since prior nephrectomy Other: - No more than 2 prior systemic therapies for metastatic renal cell carcinoma - No other concurrent investigational agents
Total Enrollment:
Location and Contact Information:
Overall Study Official:
BrianRini, Study Chair, University of California, San Francisco
UCSF Comprehensive Cancer Center
San Francisco, California, 94115
United States
Veterans Affairs Medical Center - San Francisco
San Francisco, California, 94121
United States
Additional Information:
Study ID Numbers: CDR0000069208; UCSF-NCI-5522,NCI-5522
Study Start Date:
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00030888
Other Recurrent Renal Cell Cancer Studies:
1. Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
2. Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
3. Interferon alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)
4. Interferon alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
5. Vaccine Therapy in Treating Patients With Kidney Cancer
Related Studies:
Other recurrent renal cell cancer Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer
|
|
|
|
|
|
|
|
